4,4-diphenyl-2-butanamine | 29869-77-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4,4-diphenyl-2-butanamine
• 英文别名: 3-Amino-1,1-diphenyl-butan；1-methyl-3,3-diphenyl-propylamine；(3,3-diphenyl-1-methyl propyl)-amine；4,4-Diphenylbutan-2-amine
• CAS: 29869-77-0
• 化学式: C₁₆H₁₉N
• 分子量: 225.334
• InChiKey: DJMZXBCLPVSJPI-UHFFFAOYSA-N

物化性质

• 沸点：
  341.3±31.0 °C(Predicted)
• 密度：
  1.009±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4,4-diphenyl-2-butanamine 在 甲酸 作用下， 以 水 为溶剂， 生成 [3-(4-tert-Butyl-2,6-dimethyl-phenyl)-1-methyl-propyl]-methyl-(1-methyl-3,3-diphenyl-propyl)-amine
  参考文献：
  名称：

  BE633799

  摘要：

  公开号：
• 作为产物：
  描述：

  4,4'-二苯基-2-丁酮 在 盐酸 、 ammonium formate 作用下， 生成 4,4-diphenyl-2-butanamine
  参考文献：
  名称：

  Synthesis and histamine H2 agonistic activity of arpromidine analogues: replacement of the pheniramine-like moiety by non-heterocyclic groups

  摘要：

  Analogues of the potent histamine H-2 agonist arpromidine, characterized by non-heterocyclic groups (phenyl, cyclo-hexyl, alkyl) instead of the pheniramine-like portion, were prepared and tested for their H-2 agonistic and H-1 antagonistic activity in the isolated guinea pig right atrium and ileum, respectively. In the diphenylpropylguanidine series an increase in H-2 agonistic potency resulted from mono- or difluorination at one or both phenyl rings in the meta and/or para position (pD2 less-than-or-equal-to 7.75 vs pD2 = 7.15 for the unsubstituted parent compound). Compounds chlorinated at both phenyl rings were considerably less potent. Highest combined H-2 agonistic/H-1 antagonistic potency was found in the 4-fluorophenyl series. The arpromidine analogue with cyclohexyl and methyl group instead of phenyl and pyridine ring proved to be 30 times more potent than histamine in the atrium. The H-1 antagonistic potency in cyclohexyl compounds was lower than in the diaryl series. Thus, aromatic rings appear not to be required for high H-2 agonistic potency but are useful for combined H-2 agonistic/H-1 antagonistic activity.

  DOI：

  10.1016/0223-5234(92)90145-q

文献信息

• Inhibitors of protein tyrosine phosphatase
  申请人：——

  公开号：US06410585B1

  公开（公告）日：2002-06-25

  The present invention comprises small molecular weight, non-peptidic inhibitors of formulae I-VII of Protein Tyrosine Phosphatase 1 (PTP1) which are useful for the treatment and/or prevention of Non-Insulin Dependent Diabetes Mellitus (NIDDM).

  本发明涉及蛋白酪氨酸磷酸酶1（PTP1）的式I-VII的小分子量、非肽类抑制剂，用于治疗和/或预防非胰岛素依赖型糖尿病（NIDDM）。
• Silver-Catalyzed Long-Distance Aryl Migration from Carbon Center to Nitrogen Center
  作者：Taigang Zhou、Fei-Xian Luo、Ming-Yu Yang、Zhang-Jie Shi

  DOI：10.1021/jacs.5b10267

  日期：2015.11.25

  Selective cleavage of an inert C-C bond followed by C-O/N bond formation through a long-distance aryl migration from a carbon to a nitrogen center via Ag catalysis is reported. The migration products were easily converted into γ-hydroxy amines and tetrahydroquinoline derivatives in quantitative yields. Preliminary mechanistic studies indicated a radical pathway.

  据报道，惰性 CC 键的选择性裂解，然后通过银催化从碳到氮中心的长距离芳基迁移形成 CO/N 键。迁移产物很容易转化为定量产率的 γ-羟基胺和四氢喹啉衍生物。初步的机理研究表明了一种激进的途径。
• Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use
  申请人：Sankyo Company Limited

  公开号：EP0484094A2

  公开（公告）日：1992-05-06

  Compounds of formula (I) : (in which : R1 is a hydrogen atom, an unsubstituted alkyl group, an aryl-substituted alkyl group or a heterocyclic-substituted alkyl group ; R2 is an aryl-substituted alkyl group, a heterocyclic-substituted alkyl group or a diarylamino group ; R3 is a hydrogen atom, an unsubstituted alkyl group, an aryl-substituted alkyl group or an alkenyl group having from 3 to 6 carbon atoms ; and each of the bonds represented by α-β and y-8 is a carbon-carbon single bond or a carbon-carbon double bond ;) and pharmaceutically acceptable salts and esters thereof are useful for the treatment and prophylaxis of prostatic hypertrophy. We also provide processes for their preparation.

  式(I)化合物 (其中：R1 是氢原子、未取代的烷基、芳基取代的烷基或杂环取代的烷基； R2 是芳基取代的烷基、杂环取代的烷基或二芳基氨基； R3 是氢原子、未取代的烷基、芳基取代的烷基或具有 3 至 6 个碳原子的烯基；α-β和y-8所代表的键中的每一个都是碳-碳单键或碳-碳双键；）及其药学上可接受的盐和酯可用于治疗和预防前列腺肥大。我们还提供了其制备工艺。
• Steroid derivatives for the treatment of prostatic hypertrophy, their preparation and uses
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0567271A2

  公开（公告）日：1993-10-27

  Compounds of formula (I): [wherein : R1 is hydrogen, alkyl, aryl-substituted alkyl or aromatic heterocyclic-substituted alkyl ; R2 is: aryl-substituted alkyl, aromatic heterocyclic-substituted alkyl or diarylamino; and R3 is carboxy or a group of formula -CONHS02 R4 wherein R4 is alkyl] ; and pharmaceutically acceptable salts and esters thereof have valuable 5α-reductase inhibitory activity and can thus be used for the treatment and prophylaxis of, inter alia, prostatic hypertrophy as well as other disorders arising from excess levels of 5α-dihydro-testosterone.

  式(I)化合物： [其中 ：R1 是氢、烷基、芳基取代的烷基或芳香杂环取代的烷基；R2 是：芳基取代的烷基、芳香杂环取代的烷基或二芳基氨基；以及 R3 是羧基或式 -CONHS02 R4 的基团，其中 R4 是烷基]；及其药学上可接受的盐类和酯类具有重要的 5α 还原酶抑制活性，因此可用于治疗和预防前列腺肥大以及因 5α 二氢睾酮水平过高而引起的其他疾病。
• Compounds suitable for use as intermediates in the preparation of Androst-3,5-dien-3-carboxy derivatives
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0725074A2

  公开（公告）日：1996-08-07

  A compound of formula (IV) and a process for the preparation of a compound of the following formula: in which R10 is a hydroxy group, a group -OR5, in which R5 is a carboxy protecting group, a group -NR1R2, in which R1 is hydrogen, alkyl, aryl-substituted alkyl or aromatic heterocyclic-substituted alkyl and R2 is aryl-substituted alkyl, aromatic heterocyclic-substituted alkyl or diarylamino, or a group -NRR', in which R and R' are hydrogen or alkyl.

  式(IV)化合物 以及制备下式化合物的工艺： 其中 R10 是羟基、基团-OR5（其中 R5 是羧基保护基）、基团-NR1R2（其中 R1 是氢、烷基、芳基取代的烷基或芳香杂环取代的烷基，R2 是芳基取代的烷基、芳香杂环取代的烷基或二芳基氨基）或基团-NRR'（其中 R 和 R' 是氢或烷基）。